SiSaf Announces Positive Preclinical Data in its SiS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis
Guildford, England, 12 September 2022 – SiSaf Ltd, an RNA delivery and therapeutics company, is pleased to announce positive data confirming safety and efficacy of its Bio-Courier™ next generation silicon stabilized hybrid lipid nanoparticles (sshLNP) as an effective non-viral delivery system for Autosomal Dominant Osteopetrosis 2 (ADO2) siRNA therapy.
